Nyxoah SA (NASDAQ:NYXH) Short Interest Update

Nyxoah SA (NASDAQ:NYXH) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 160,000 shares, anincreaseof29.9% from the July 15th total of 123,200 shares. Currently,0.9% of the company’s shares are short sold. Based on an average daily volume of 86,300 shares, the short-interest ratio is presently 1.9 days. Based on an average daily volume of 86,300 shares, the short-interest ratio is presently 1.9 days. Currently,0.9% of the company’s shares are short sold.

Hedge Funds Weigh In On Nyxoah

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in Nyxoah by 72.4% in the second quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after buying an additional 3,303 shares during the period. Raymond James Financial Inc. acquired a new position in Nyxoah in the second quarter valued at $70,000. LPL Financial LLC acquired a new position in Nyxoah in the fourth quarter valued at $102,000. Walleye Capital LLC lifted its holdings in Nyxoah by 23.9% in the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after buying an additional 2,862 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Nyxoah in the fourth quarter valued at $135,000.

Nyxoah Price Performance

Shares of NASDAQ:NYXH opened at $6.43 on Friday. The firm has a market cap of $219.01 million, a PE ratio of -2.80 and a beta of 1.61. The firm’s fifty day moving average is $7.44 and its 200-day moving average is $7.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.35 and a current ratio of 2.63. Nyxoah has a 52 week low of $5.55 and a 52 week high of $11.87.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Monday, August 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). The business had revenue of $1.58 million for the quarter, compared to analyst estimates of $1.33 million. Nyxoah had a negative return on equity of 79.18% and a negative net margin of 1,541.84%. Sell-side analysts predict that Nyxoah will post -1.91 earnings per share for the current year.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.